Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04845178 · ClinicalTrials.gov registry record · Phase 2
Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults
A Phase 2 study, sponsored by AEON Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 797
- Enrollment target
NCT04845178: Completed Phase 2 study, sponsored by AEON Biopharma.
NCT04845178 is a Phase 2 study that has completed, run by AEON Biopharma. The registered enrollment target is 797 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (499% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04845178, a Phase 2 study, has completed, sponsored by AEON Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 797 participants
- Enrollment target
Study Summary
This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 765 patients across approximately 64 sites in the United States, Canada and Australia. Study subjects will be divided evenly across a low dose group, a high dose group and a placebo group. All patients will receive two treatment cycles of ABP-450 or placebo utilizing the Company's novel injection paradigm.
Primary Outcome
The primary efficacy endpoint will be the change in mean Monthly Migraine Days (MMD) from the 4-week Baseline period to Weeks 21 to 24 Treatment period.
Interventions
- DRUG Placebo
- DRUG ABP-450
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 797 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2024-08-06 |
| Phase | Phase 2 |
What the finished NCT04845178 record still lists
NCT04845178 is an interventional study that assigns participants to a tested intervention. The registered 797 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (499% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04845178 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04845178 about?
NCT04845178 is a clinical study titled "Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults". This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 765 patients across approximately 64 sites in the United States, Canada and Australia. Study subjects will be divided evenl...
What is the current status of trial NCT04845178?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 797 participants. The study started on 2021-03-01. Estimated completion is 2024-08-06.
What interventions are being tested in trial NCT04845178?
The interventions under investigation include: Placebo (DRUG), ABP-450 (DRUG).
Who is sponsoring clinical trial NCT04845178?
This trial is sponsored by AEON Biopharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04845178's enrollment target sits among peer trials
797 40th of 2000 higher than 1,961 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06051058 · 798 participants · NA
Care Transitions App for Patients With Multiple Chronic Conditions
- NCT05150691 · 796 participants · Phase 1
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- NCT06208150 · 795 participants · Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- NCT06724172 · 795 participants · NA
CHIME: Comparing Health Interventions for Maternal Equity
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI